Literature DB >> 25917204

Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results.

V Granata1, R Fusco1, M Piccirillo2, R Palaia2, A Petrillo1, S Lastoria3, F Izzo4.   

Abstract

OBJECTIVE: Report the preliminary results on electrochemotherapy (ECT) in the treatment of locally advanced pancreatic cancer of a phase I/II study and described the new functional imaging tools to assess ECT response in Magnetic Resonance (MR) imaging compared to morphological Computer Tomography (CT), ultrasound (US) without and with contrast enhancement (CEUS) and MR Imaging.
MATERIALS AND METHODS: Thirteen patients were enrolled in an ongoing clinical phase I/II study approved by Ethical Committee of National Cancer Institute G. Pascale Foundation - IRCCS of Naples. ECT with bleomycin was performed during open surgery. All patients underwent US and CT scan, before and after ECT treatment; 7 patients were evaluated using morphological and functional (dynamic contrast enhancement-DCE and diffusion weighted- DW) parameters in MR; 5 patients underwent CEUS. RECIST criteria were used to evaluate ECT response on US, CT and MR images. Functional parameters were also used to evaluate ECT response on MR images.
RESULTS: No acute (intraoperative) and/or postoperative serious adverse events related to electrochemotherapy were observed; no clinically significant electrocardiographic, hemodynamic, or serum biologic changes were noted. No clinically relevant elevation of amylase or lipase levels was observed and no bleeding or damage to surrounding viscera occurred. In three patients had seen splenic infarction without thrombosis of the splenic vessels.
CONCLUSION: Electrochemotherapy is feasible and safe treatment modality in patients with locally advanced pancreatic adenocarcinoma. Dynamic and diffusion MR imaging in comparison to MR morphological sequence alone and to UC and CT imaging is more suitable to assess ECT treatment response. CEUS is not indicated in follow up after ECT.
Copyright © 2015 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Electrochemotherapy; Pancreatic adenocarcinoma; Safety; Treatment assessment

Mesh:

Substances:

Year:  2015        PMID: 25917204     DOI: 10.1016/j.ijsu.2015.04.055

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  34 in total

1.  Electrochemotherapy for Pancreatic Cancer: An Emerging Treatment Modality?

Authors:  Jin He
Journal:  Ann Surg Oncol       Date:  2020-07-04       Impact factor: 5.344

Review 2.  Management of cutaneous melanoma: radiologists challenging and risk assessment.

Authors:  Vincenza Granata; Igino Simonetti; Roberta Fusco; Sergio Venanzio Setola; Francesco Izzo; Luigi Scarpato; Vito Vanella; Lucia Festino; Ester Simeone; Paolo Antonio Ascierto; Antonella Petrillo
Journal:  Radiol Med       Date:  2022-07-14       Impact factor: 6.313

3.  Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study.

Authors:  Luciano Tarantino; Giuseppina Busto; Aurelio Nasto; Raffaele Fristachi; Luigi Cacace; Maria Talamo; Catello Accardo; Sara Bortone; Paolo Gallo; Paolo Tarantino; Riccardo Aurelio Nasto; Matteo Nicola Dario Di Minno; Pasquale Ambrosino
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

4.  Results of Dynamic Contrast-Enhanced Ultrasound Correlate With Treatment Outcome in Canine Neoplasia Treated With Electrochemotherapy and Interleukin-12 Plasmid Electrotransfer.

Authors:  Maja Brloznik; Simona Kranjc Brezar; Nina Boc; Tanja Knific; Maja Cemazar; Nina Milevoj; Gregor Sersa; Natasa Tozon; Darja Pavlin
Journal:  Front Vet Sci       Date:  2021-05-20

Review 5.  A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response.

Authors:  Vincenza Granata; Roberta Fusco; Simona Salati; Antonella Petrillo; Elio Di Bernardo; Roberta Grassi; Raffaele Palaia; Ginevra Danti; Michelearcangelo La Porta; Matteo Cadossi; Gorana Gašljević; Gregor Sersa; Francesco Izzo
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

6.  Reduction of muscle contraction and pain in electroporation-based treatments: An overview.

Authors:  Roberta Fusco; Elio Di Bernardo; Valeria D'Alessio; Simona Salati; Matteo Cadossi
Journal:  World J Clin Oncol       Date:  2021-05-24

7.  Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth.

Authors:  Sabrina Bimonte; Maddalena Leongito; Antonio Barbieri; Vitale Del Vecchio; Massimiliano Barbieri; Vittorio Albino; Mauro Piccirillo; Alfonso Amore; Raimondo Di Giacomo; Aurelio Nasto; Vincenza Granata; Antonella Petrillo; Claudio Arra; Francesco Izzo
Journal:  Infect Agent Cancer       Date:  2015-07-29       Impact factor: 2.965

Review 8.  Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review.

Authors:  Luca G Campana; A James P Clover; Sara Valpione; Pietro Quaglino; Julie Gehl; Christian Kunte; Marko Snoj; Maja Cemazar; Carlo R Rossi; Damijan Miklavcic; Gregor Sersa
Journal:  Radiol Oncol       Date:  2016-02-16       Impact factor: 2.991

Review 9.  Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies.

Authors:  Sabrina Bimonte; Maddalena Leongito; Vincenza Granata; Antonio Barbieri; Vitale Del Vecchio; Michela Falco; Aurelio Nasto; Vittorio Albino; Mauro Piccirillo; Raffaele Palaia; Alfonso Amore; Raimondo di Giacomo; Secondo Lastoria; Sergio Venanzio Setola; Roberta Fusco; Antonella Petrillo; Francesco Izzo
Journal:  Radiol Oncol       Date:  2016-02-16       Impact factor: 2.991

10.  Cell Electrosensitization Exists Only in Certain Electroporation Buffers.

Authors:  Janja Dermol; Olga N Pakhomova; Andrei G Pakhomov; Damijan Miklavčič
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.